<DOC>
	<DOCNO>NCT01808092</DOCNO>
	<brief_summary>The purpose study evaluate effect Ceftazidime-Avibactam compare Meropenem treat hospitalize adult nosocomial pneumonia include ventilator-associated pneumonia</brief_summary>
	<brief_title>A Study Comparing Ceftazidime-Avibactam Versus Meropenem Hospitalized Adults With Nosocomial Pneumonia</brief_title>
	<detailed_description>A Phase III , Randomized , Multicentre , Double-blind , Double-dummy , Parallel-group Comparative Study Determine Efficacy , Safety And Tolerability Ceftazidime-Avibactam Versus Meropenem Treatment Nosocomial Pneumonia Including Ventilator-Associated Pneumonia Hospitalized Adults</detailed_description>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Ventilator-Associated</mesh_term>
	<mesh_term>Meropenem</mesh_term>
	<mesh_term>Thienamycins</mesh_term>
	<mesh_term>Ceftazidime</mesh_term>
	<mesh_term>Avibactam</mesh_term>
	<mesh_term>Avibactam , ceftazidime drug combination</mesh_term>
	<criteria>18 90 year age inclusive Females participate surgically sterile complete menopause ; able child , must negative serum pregnancy test , agree attempt pregnancy use acceptable contraception receive study therapy 1 week Onset symptom â‰¥ 48 hour admission &lt; 7 day discharge inpatient acute chronic care facility New worsen infiltrate chest Xray obtain within 48 hour prior randomization At least 1 follow systemic sign : Fever ( temperature &gt; 38 C ) hypothermia ( rectal/core temperature &lt; 35 C ) ; White blood cell count &gt; 10,000 cells/mm3 , White blood cell count &lt; 4500 cells/mm3 , &gt; 15 % band form . Pulmonary disease , investigator 's judgment , would preclude evaluation therapeutic response ( e.g . lung cancer , active tuberculosis , cystic fibrosis , granulomatous disease , fungal pulmonary infection recent pulmonary embolism ) . Patients lung abscess , pleural empyema post obstructive pneumonia . Patients estimate creatinine clearance &lt; 16ml/min Cockcroft Gault formula patient expect require haemodialysis renal support study therapy . Acute hepatitis prior 6 month , cirrhosis , acute hepatic failure acute decompensation chronic hepatic failure . Patients receive hemodialysis peritoneal dialysis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Ceftazidime ,</keyword>
	<keyword>Meropenem ,</keyword>
	<keyword>Anti-Bacterial Agents ,</keyword>
	<keyword>Anti-Infective Agents ,</keyword>
	<keyword>Therapeutic Uses ,</keyword>
	<keyword>Pharmacologic Actions ,</keyword>
	<keyword>Physiological Effects Drugs</keyword>
</DOC>